Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Jeffrey Dayno Sells 25,933 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
04:44am, Friday, 19'th Dec 2025
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) CEO Jeffrey Dayno sold 25,933 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price
Harmony Biosciences (NASDAQ:HRMY) Shares Down 3.9% Following Insider Selling
01:32am, Friday, 19'th Dec 2025
Shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) were down 3.9% on Thursday following insider selling activity. The stock traded as low as $37.47 and last traded at $37.25
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRM
Federated Hermes Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY
03:52am, Friday, 12'th Dec 2025
Federated Hermes Inc. cut its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 33.2% during the second quarter, according to the company in its most recent 13F filing with the Securiti
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
08:05am, Monday, 08'th Dec 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY
04:18am, Friday, 05'th Dec 2025
Capital Fund Management S.A. bought a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) during the second quarter, according to the company in its most recent disclosure with the Securiti
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-
Boston Partners Takes $19.40 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
04:03am, Saturday, 29'th Nov 2025
Boston Partners purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent filing with the Securities
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by American Century Companies Inc.
03:18am, Saturday, 29'th Nov 2025
American Century Companies Inc. grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 16.5% in the second quarter, according to its most recent disclosure with the SEC. The fund ow
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
08:05am, Monday, 24'th Nov 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resis
Envestnet Asset Management Inc. Sells 15,944 Shares of Harmony Biosciences Holdings, Inc. $HRMY
04:20am, Friday, 21'st Nov 2025
Envestnet Asset Management Inc. decreased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 27.3% during the undefined quarter, according to its most recent filing with th
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational,
Harmony Biosciences to Participate in Upcoming Investor Conferences
08:05am, Tuesday, 18'th Nov 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conference
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
02:06pm, Tuesday, 04'th Nov 2025
Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP &
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
09:41am, Tuesday, 04'th Nov 2025
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a y
